The startup develops RNA therapy targeting long non-coding RNAs to create diagnostic markers and therapeutic agents for breast, colorectal, and liver cancers. This approach aims to enhance treatment precision and improve patient outcomes in common cancer types.
Funding
$14M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer diagnostics and treatments often lack the precision needed to effectively target specific cancer subtypes, leading to suboptimal patient outcomes and potential side effects. Traditional methods may not adequately address the complexities of gene expression in different cancer types, hindering the development of more targeted therapies.
Solution
This startup is developing RNA-based therapeutics and diagnostic markers that target long non-coding RNAs (lncRNAs) to improve the precision of cancer treatment. By focusing on lncRNAs, which play a crucial role in gene regulation and cancer development, the company aims to create more effective and personalized therapies for breast, colorectal, and liver cancers. Their approach involves identifying and targeting specific lncRNAs that are dysregulated in these cancers, allowing for the development of diagnostic tools that can detect cancer early and therapeutic agents that can selectively kill cancer cells while sparing healthy tissue. This targeted approach has the potential to enhance treatment efficacy, reduce side effects, and improve overall patient outcomes.
Target Audience
The primary target audience includes oncologists, pathologists, and pharmaceutical companies involved in cancer diagnostics and therapeutics, as well as patients with breast, colorectal, and liver cancers.
Features
- Identification of novel lncRNA targets specific to breast, colorectal, and liver cancers.
- Development of RNA-based therapeutics designed to selectively inhibit or modulate the activity of target lncRNAs.
- Creation of diagnostic assays that utilize lncRNA expression patterns to detect cancer early and predict treatment response.
- In vitro and in vivo validation of therapeutic efficacy and safety.
- Proprietary platform for lncRNA target discovery and drug development.